Srivani Ravoori, PhD

Srivani Ravoori, PhD, is associate director of science communications at the AACR. Ravoori is an experienced science content developer and an expert in translating complex cancer science into simple language with the goal of educating the public, media, policymakers, and the health care industry about the importance of cancer research. She guides the Communications and Public Relations department in identifying the latest cancer research advances and disseminate them through various print and social media platforms. She holds a PhD degree in cancer biology and dedicated the first 15 years of her career to conducting basic and translational cancer research.

Harnessing the Power of Precision Medicine – Treating Cancers with Tissue-agnostic Therapies

Cancer treatments have been, and continue to be in most cases, based on the organ site where the tumor originates—some treatments are specific for breast cancer, some for lung cancer, and so on. However, rapid advances in genomic sequencing technologies have led to a recent development that deviates from the long-held notion of treating cancers based on the site of origin.

Read More

AACR Annual Meeting 2018: Off-the-shelf CAR T-cell Immunotherapy – Are we There Yet?

A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …

Read More

Improving the Effectiveness of CAR T-cell Immunotherapy

A study presented in the AACR Annual Meeting 2018 Media Preview webinar, held March 15, examined closely a key ingredient necessary to make effective chimeric antigen receptor (CAR) T cells – the T cells of a patient. The researchers behind this study have identified one potential reason for why we have not been successful in making CAR T-cell therapy work against solid tumors, and offer a solution.

Read More

Experts Forecast Cancer Research and Treatment Advances in 2018

This past year has been a year of many “firsts” for the oncology community, with several revolutionary advances in the research and treatment of cancer, We asked experts in the fields of immunotherapy, precision medicine, and prevention and disparities research where the cancer research community is headed next and what major accomplishments we might expect in 2018 to take us closer to conquering cancer.

Read More

Learning From the Immune System of Long-term Pancreatic Cancer Survivors

Pancreatic cancer is a deadly disease with a five-year survival rate of a mere 8.2 percent, according to statistics from the SEER database. Unfortunately, the last 30 years has not seen any significant improvement in survival for patients with this disease. Pancreatic cancer is projected to become the second leading cause of deaths due to cancer in the United States by 2030.

Read More

Treating DNA Repair-deficient Breast Cancers

Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.

Read More

Recent Advances in Measuring Response to Immune Checkpoint Inhibitors

In recent years, the U.S. Food and Drug Administration has approved immune checkpoint inhibitors, a class of immunotherapy, to treat 10 different types of cancer, in addition to solid tumors located anywhere in the body that have certain DNA damage and repair-related biomarkers. However, only a small percentage of patients respond to these treatments, and they can have significant side effects. Researchers are looking for biomarkers that can identify patients who are likely to respond to immune checkpoint inhibitors.

Read More